REG - AstraZeneca PLC - Imfinzi improved EFS in resectable lung cancer

AstraZenecaAnnouncement

09/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230309:nRSI3664Sa&default-theme=true

RNS Number : 3664S  AstraZeneca PLC  09 March 2023

 

9 March 2023 07:00 GMT

 

Imfinzi significantly improved event-free survival in AEGEAN

Phase III trial for patients with resectable non-small cell lung cancer

 

 Results showed that Imfinzi-based treatment before and after surgery
significantly increased the time patients live without recurrence or
progression events

 

Positive high-level results from a planned interim analysis of the AEGEAN
Phase III, placebo- controlled trial showed that treatment with AstraZeneca's
Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before
surgery and as adjuvant monotherapy after surgery demonstrated a statistically
significant and clinically meaningful improvement in event-free survival (EFS)
versus neoadjuvant chemotherapy alone followed by surgery for patients with
resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC).

 

Results from the final pathologic complete response (pCR) and major pathologic
response (mPR) analyses were consistent with previously announced
(https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-improved-pcr-in-resectable-lung-cancer.html)
positive results. The trial will continue as planned to assess key secondary
endpoints including disease-free survival (DFS) and overall survival (OS).

 

Each year there are an estimated 2.2 million people diagnosed with lung cancer
globally with 80-85% of patients diagnosed with NSCLC, the most common form of
lung cancer.(1-3) Approximately 25-30% of all patients with NSCLC are
diagnosed early enough to have surgery with curative intent.(4-5) However,
only around 56-65% of patients with Stage II disease will survive for five
years.(6) This decreases to 41% for patients with Stage IIIA and 24% for
patients with Stage IIIB disease, reflecting a high unmet medical need.(6)

 

John V. Heymach, MD, PhD. Professor and Chair Thoracic/Head and Neck Medical
Oncology, The University of Texas MD Anderson Cancer Center, said: "Treating
patients early with durvalumab both before and after surgery delivers a
significant and clinically meaningful benefit in resectable non-small cell
lung cancer, where new options are urgently needed to offer patients the best
chance of long-term survival. The AEGEAN results provide compelling evidence
that this novel durvalumab regimen can drive improved outcomes in this
curative-intent setting."

 

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca,
said: "Patients with resectable non-small cell lung cancer face unacceptably
high rates of recurrence, despite treatment with chemotherapy and surgery. We
have shown that adding Imfinzi both before and after surgery significantly
increased the time patients live without recurrence or progression events. We
will continue to follow patients for overall survival."

 

Imfinzi was well tolerated and no new safety concerns were observed in the
neoadjuvant and adjuvant settings. Further, adding Imfinzi to neoadjuvant
chemotherapy was consistent with the known profile for this combination and
did not increase complications or adverse events, or compromise patients'
ability to undergo surgery versus chemotherapy alone.

 

These data will be presented at a forthcoming medical meeting and shared with
global health authorities.

 

AstraZeneca has a comprehensive portfolio of approved and potential new
medicines in development for patients with lung cancer. In addition to these
results, the Company is also announcing today that Tagrisso (osimertinib) met
a secondary endpoint of OS in the ADAURA Phase III trial in early-stage (IB,
II and IIIA) epidermal growth factor receptor-mutated (EGFRm) NSCLC after
complete tumour resection with curative intent.

 

Notes

 

Lung cancer

Lung cancer is the leading cause of cancer death among both men and women,
accounting for about one-fifth of all cancer deaths.(1) Lung cancer is broadly
split into NSCLC and small cell lung cancer (SCLC).(2) The majority of NSCLC
patients are diagnosed with advanced disease while approximately 25-30%
present with resectable disease at diagnosis.(4-5) Early-stage lung cancer
diagnoses are often only made when the cancer is found on imaging for an
unrelated condition.(7-8)

 

For patients with resectable tumours, the majority eventually develop
recurrence despite complete tumour resection and adjuvant chemotherapy.(9)

 

AEGEAN

AEGEAN is a randomised, double-blind, multi-centre, placebo-controlled global
Phase III trial evaluating Imfinzi as perioperative treatment for patients
with resectable Stage IIA-IIIB (Eighth Edition AJCC Cancer Staging Manual)
NSCLC, irrespective of PD-L1 expression. Perioperative therapy includes
treatment before and after surgery, also known as neoadjuvant/adjuvant
therapy. In the trial, 802 patients were randomised to receive a 1500mg fixed
dose of Imfinzi plus chemotherapy or placebo plus chemotherapy every three
weeks for four cycles prior to surgery, followed by Imfinzi or placebo every
four weeks (for up to 12 cycles) after surgery. Patients with known EGFR or
ALK genomic tumour aberrations were excluded from the primary efficacy
analyses.

 

In the AEGEAN trial, the primary endpoints were pCR, defined as no viable
tumour in the resection specimen (including lymph nodes) following neoadjuvant
therapy, and EFS, defined as the time from randomisation to an event like
tumour recurrence, progression precluding definitive surgery, or death. Key
secondary endpoints were mPR, defined as residual viable tumour of less than
or equal to 10% in the resected primary tumour following neoadjuvant therapy,
DFS, OS, safety and quality of life. The final pathologic response analyses
were performed after all patients had the opportunity for surgery and
pathology assessment per the trial protocol. The trial enrolled participants
in 264 centres in more than 25 countries including in the US, Canada, Europe,
South America and Asia.

 

Imfinzi

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1
protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins,
countering the tumour's immune-evading tactics and releasing the inhibition of
immune responses.

 

Imfinzi is the only approved immunotherapy and the global standard of care in
the curative-intent setting of unresectable, Stage III NSCLC in patients whose
disease has not progressed after chemoradiation therapy based on the PACIFIC
Phase III trial.

 

Imfinzi is also approved in the US, EU, Japan, China and many other countries
around the world for the treatment of extensive-stage SCLC based on the
CASPIAN Phase III trial. In an exploratory analysis in 2021, updated results
from the CASPIAN trial showed Imfinzi plus chemotherapy tripled patient
survival at three years versus chemotherapy alone. Additionally, Imfinzi is
approved in combination with a short course of Imjudo (tremelimumab) and
chemotherapy for the treatment of metastatic NSCLC in the US, EU and Japan
based on the POSEIDON Phase III trial.

 

In addition to its indications in lung cancer, Imfinzi is also approved in
combination with chemotherapy in locally advanced or metastatic biliary tract
cancer in the US, EU, Japan and several other countries; in combination with
Imjudo in unresectable hepatocellular carcinoma in the US, EU and Japan; and
in previously treated patients with advanced bladder cancer in several
countries.

 

Since the first approval in May 2017, more than 150,000 patients have been
treated with Imfinzi.

 

AstraZeneca has several ongoing registrational trials focused on testing
Imfinzi in earlier stages of lung cancer, including in resectable NSCLC
(ADJUVANT BR.31) and unresectable NSCLC (PACIFIC-2, 4, 5, 8 and 9), and in
limited-stage SCLC (ADRIATIC).

 

As part of a broad development programme, Imfinzi is being tested as a single
treatment and in combinations with other anti-cancer treatments for patients
with SCLC, NSCLC, bladder cancer, several gastrointestinal (GI) cancers,
ovarian cancer, endometrial cancer and other solid tumours.

 

AstraZeneca in lung cancer

AstraZeneca is working to bring patients with lung cancer closer to cure
through the detection and treatment of early-stage disease, while also pushing
the boundaries of science to improve outcomes in the resistant and advanced
settings. By defining new therapeutic targets and investigating innovative
approaches, the Company aims to match medicines to the patients who can
benefit most.

 

The Company's comprehensive portfolio includes leading lung cancer medicines
and the next wave of innovations, including Tagrisso and Iressa (gefitinib);
Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan) and datopotamab
deruxtecan in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in
collaboration with HUTCHMED; as well as a pipeline of potential new medicines
and combinations across diverse mechanisms of action.

 

AstraZeneca is a founding member of the Lung Ambition Alliance, a global
coalition working to accelerate innovation and deliver meaningful improvements
for people with lung cancer, including and beyond treatment.

 

AstraZeneca in immuno-oncology (IO)

AstraZeneca is a pioneer in introducing the concept of immunotherapy into
dedicated clinical areas of high unmet medical need. The Company has a
comprehensive and diverse IO portfolio and pipeline anchored in
immunotherapies designed to overcome evasion of the anti-tumour immune
response and stimulate the body's immune system to attack tumours.

 

AstraZeneca aims to reimagine cancer care and help transform outcomes for
patients with Imfinzi as a single treatment and in combination with Imjudo as
well as other novel immunotherapies and modalities. The Company is also
exploring next-generation immunotherapies like bispecific antibodies and
therapeutics that harness different aspects of immunity to target cancer.

 

AstraZeneca is boldly pursuing an innovative clinical strategy to bring
IO-based therapies that deliver long-term survival to new settings across a
wide range of cancer types. With an extensive clinical programme, the Company
also champions the use of IO treatment in earlier disease stages, where there
is the greatest potential for cure.

 

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand cancer and
all its complexities to discover, develop and deliver life-changing medicines
to patients.

 

The Company's focus is on some of the most challenging cancers. It is through
persistent innovation that AstraZeneca has built one of the most diverse
portfolios and pipelines in the industry, with the potential to catalyse
changes in the practice of medicine and transform the patient experience.

 

AstraZeneca has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

References

1.   World Health Organisation. International Agency for Research on Cancer.
Lung Fact Sheet. Available at:
https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf
(https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf) .
Accessed March 2023.

2.   LUNGevity Foundation. Types of Lung Cancer. Available at:
https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer
(https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer)
. Accessed March 2023.

3.   Cheema PK, et al. Perspectives on treatment advances for stage III
locally advanced unresectable non-small-cell lung cancer. Curr
Oncol. 2019;26(1):37-42.

4.   Cagle PT, et al. Lung Cancer Biomarkers: Present Status and Future
Developments. Arch Pathol Lab Med. 2013;137(9):1191-1198.

5.   Le Chevalier T. Adjuvant Chemotherapy for Resectable Non-Small-Cell
Lung Cancer: Where is it Going? Ann Oncol. 2010;21:vii196-198.

6.   Goldstraw P, et al. The IASLC Lung Cancer Staging Project: Proposals
for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of
the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51.

7.   Sethi S, et al. Incidental Nodule Management - Should There Be a Formal
Process? J Thorac Onc. 2016:8;S494-S497.

8.   LUNGevity Foundation. Screening and Early Detection. Available at:
https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection
(https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection)
. Accessed March 2023.

9.   Pignon JP, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis
by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUWRAROBUORUR